
Cellular immunotherapy
Cellular immunotherapy – including Chimeric Antigen Receptor (CAR) T-cell therapy and Tumour Infiltrating Lymphocyte (TIL) therapy – have changed survival outcomes. These therapies aim to leverage the body’s own immune cells to seek and destroy cancer, without harming healthy cells.
• For large B-cell lymphoma that is resistant to chemotherapy, survival beyond five years has jumped from 0% to over 40%.
• For advanced melanoma, five-year survival for those who do not respond to the standard checkpoint immunotherapies has improved to 20%, where once it was nearly 0%.